-
Toremifene versus Tamoxifen for Advanced Breast Cancer
2026-09-17
The Cochrane review directly compared two selective estrogen receptor modulators in advanced breast cancer and found no persuasive evidence that toremifene was superior to tamoxifen for tumor response, disease control, progression, or overall survival. Its main contribution is a structured synthesis of head-to-head trial evidence, showing how endpoint selection, trial quality, and adverse-event interpretation should shape conclusions about endocrine therapy.
-
HMGCS2, LysoPC, and Pulmonary Fibrosis
2026-09-17
Yang et al. identify a cell-specific mechanism in which loss of HMGCS2 disrupts lipid degradation in type II alveolar epithelial cells, increasing LysoPC release and activating lung fibroblasts. The study connects epithelial lipid metabolism to fibrosis progression and provides a framework for lipid signaling pathway analysis using defined lysophospholipid perturbations.
-
Amyloid Beta-Peptide (1-40): Research Guide
2026-09-16
Amyloid Beta-Peptide (1-40) (human) is a synthetic 40-residue Aβ40 model for Alzheimer’s disease research. Its defined identity, reported solubility, and storage requirements support controlled amyloid fibril formation study, while calcium-dependent aggregation findings help define experimental limits.
-
Gap19: From Cx43 Biology to Assay Strategy
2026-09-16
Gap19 is a selective connexin 43 hemichannel blocker that connects channel biology with neuroinflammatory assay design. This article interprets macrophage NF-κB findings alongside astrocyte and cerebral ischemia evidence to clarify what the peptide can—and cannot—establish experimentally.
-
LY2886721: Practical BACE Inhibitor Workflows
2026-09-15
LY2886721 supports controlled BACE1 enzyme inhibition across biochemical, neuronal, and translational Alzheimer’s disease research workflows. Its strongest use-case is not simply maximal amyloid beta reduction, but measuring how graded pathway suppression affects APP processing, secreted biomarkers, and synaptic function.
-
Amyloid β-Peptide (1-42) (human): Lab Guide
2026-09-15
A practical, evidence-based guide to using Amyloid β-Peptide (1-42) (human), SKU B6057, in neuronal viability, microglial uptake, and ion-channel experiments. It connects product handling specifications with published Aβ1–42 biology to improve assay interpretation, preparation consistency, and vendor selection.
-
YM 58483 (BTP2) SOCE Research Workflows
2026-09-14
YM 58483 (BTP2) gives researchers a practical way to test whether store-operated Ca2+ entry drives immune activation or fibrosis-associated signaling. This workflow-focused guide covers concentration planning, calcium and NFAT readouts, salivary-gland fibrosis models, and troubleshooting for interpretable SOCE blockade.
-
Reparixin and the IL-8–CXCR1 Translational Axis
2026-09-14
A mechanistic and translational framework for using Reparixin, a CXCR1/2 inhibitor, to interrogate IL-8 signaling across neutrophil biology, tissue injury, and microbial oncology.
-
HMGCS2, Lyso-PC, and Pulmonary Fibrosis
2026-09-13
Yang et al. identify injured alveolar type II epithelial cells as a major source of lipid accumulation in bleomycin-associated pulmonary fibrosis and show that released lysophosphatidylcholines activate lung fibroblasts. Their mechanistic data connect reduced epithelial HMGCS2 to impaired lipid degradation through a PPARα–CPT1A/CPT2 axis, providing a framework for studying epithelial–fibroblast crosstalk and lipid-mediated fibrosis.
-
LL-37, KE-18, and KR-12: Selective Biofilm Activity
2026-09-12
Luo and colleagues compared LL-37 with the truncated mimetics KE-18 and KR-12, showing that planktonic killing and biofilm control are not interchangeable peptide activities. The study provides a useful framework for selecting KR-12 human antimicrobial peptide assays while emphasizing that activity depends on organism, biofilm stage, and experimental endpoint.
-
CTCF, Centromere Function, and Mitotic Fidelity
2026-09-11
This study uses rapid, inducible CTCF degradation to show that CTCF maintains centromere architecture rather than primarily recruiting CENP-E to kinetochores. The findings connect CTCF loss with disorganized metaphase alignment, increased intercentromere distance, mitotic failure, and abnormal post-mitotic nuclear shape.
-
Reprogramming Myeloma Immunity with Lenalidomide
2026-09-11
Lenalidomide (CC-5013) is more than a cytotoxicity tool: its immunomodulatory activity can be interpreted through an epigenetic–innate immune framework. Recent DOT1L research shows how mechanistic combination assays may improve multiple myeloma research, biomarker development, and translational decision-making.
-
EGF Signaling as a Translational Assay Lever
2026-09-10
Recombinant human EGF is more than a routine culture supplement: it is a defined biological input that can improve assay interpretability across epithelial, stemness, repair, and oncology models. This article connects EGF receptor biology with the MYC–EphA2 synthetic-lethal findings reported in a recent breast cancer study, while defining practical controls, product-selection criteria, and the boundaries of translational inference.
-
4-Phenylbutyric acid in Reliable ER Stress Assays
2026-09-10
This scenario-driven guide explains how 4-Phenylbutyric acid (SKU C6831) can help researchers interpret ER-stress-linked changes in viability, proliferation, apoptosis, and ferroptosis assays. It combines practical formulation guidance with quantitative findings from a recent HK-2 kidney injury study and emphasizes controls, documentation, and reproducibility.
-
1-myristoylglycerophosphocholine in Fibrosis Assays
2026-09-09
Use 1-myristoylglycerophosphocholine, also known as 14:0 Lyso-PC, as a defined lysophospholipid challenge for separating epithelial lipid remodeling from fibroblast activation. This workflow combines conditioned-medium experiments, direct lipid exposure, lipid signaling pathway analysis, and formulation controls for more interpretable fibrosis and smooth muscle studies.